Product Description
Valrubicin solution is used to treat a type of bladder cancer (carcinoma in situ; CIS) that was not effectively treated with another medication (Bacillus Calmette-Guerin; BCG therapy) in patients that can not have surgery right away to remove all or part of the bladder. However, only about 1 out of 5 patients responds to treatment with valrubicin and delaying bladder surgery may lead to the spread of bladder cancer which may be life-threatening. Valrubicin is an anthracycline antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells in your body. (Sourced from: https://medlineplus.gov/druginfo/meds/a611021.html)
Mechanisms of Action: PK Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|